A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial

(2014) A. Radhakrishnan et al.   JOURNAL OF CHEMOTHERAPY

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer

(2010) Rogerio Lilenbaum et al.   Journal of Thoracic Oncology

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

(2009) Myung Hee Chang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

(2009) Jyoti D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

(2008) Rebecca Suk Heist et al.   Journal of Thoracic Oncology

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study

(2008) Kaoru Kubota et al.   LANCET ONCOLOGY

An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients

(2008) J. Trédaniel et al.   LUNG CANCER